Yidong Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yidong Zhu has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Hongna Wang
Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China
1 shared publication - Huiyan Liu
Affiliated Cancer Hospital, Institute of Guangzhou Medical University, Guangzhou 510095, China
1 shared publication - Tianxiang Liang
Affiliated Cancer Hospital, Institute of Guangzhou Medical University, Guangzhou 510095, China
1 shared publication - Yongjie Wei
Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 17 April 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (4) , 601
Advances in Drug Discovery Targeting Lysosomal Membrane Proteins
Lysosomes are essential organelles of eukaryotic cells and are responsible for various cellular functions, including endocytic degradation, extracellular secretion, and signal transduction. There are dozens of proteins localized to the lysosomal membrane that control the transport of ions and substances across the membrane and are integral to lysosomal function. Mutations or aberrant expression of these proteins trigger a variety of disorders, making them attractive targets for drug development for lysosomal disorder-related diseases. However, breakthroughs in R&D still await a deeper understanding of the underlying mechanisms and processes of how abnormalities in these membrane proteins induce related diseases. In this article, we summarize the current progress, challenges, and prospects for developing therapeutics targeting lysosomal membrane proteins for the treatment of lysosomal-associated diseases.
- 17 April 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (4) , 601
Open AccessAdvances in Drug Discovery Targeting Lysosomal Membrane Proteins
Lysosomes are essential organelles of eukaryotic cells and are responsible for various cellular functions, including endocytic degradation, extracellular secretion, and signal transduction. There are dozens of proteins localized to the lysosomal membrane that control the transport of ions and substances across the membrane and are integral to lysosomal function. Mutations or aberrant expression of these proteins trigger a variety of disorders, making them attractive targets for drug development for lysosomal disorder-related diseases. However, breakthroughs in R&D still await a deeper understanding of the underlying mechanisms and processes of how abnormalities in these membrane proteins induce related diseases. In this article, we summarize the current progress, challenges, and prospects for developing therapeutics targeting lysosomal membrane proteins for the treatment of lysosomal-associated diseases.